196 related articles for article (PubMed ID: 37683735)
1. AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation.
Norman JS; Li PJ; Kotwani P; Shui AM; Yao F; Mehta N
J Hepatol; 2023 Dec; 79(6):1469-1477. PubMed ID: 37683735
[TBL] [Abstract][Full Text] [Related]
2. Combinations of biomarkers and Milan criteria for predicting hepatocellular carcinoma recurrence after liver transplantation.
Chaiteerakij R; Zhang X; Addissie BD; Mohamed EA; Harmsen WS; Theobald PJ; Peters BE; Balsanek JG; Ward MM; Giama NH; Moser CD; Oseini AM; Umeda N; Venkatesh S; Harnois DM; Charlton MR; Yamada H; Satomura S; Algeciras-Schimnich A; Snyder MR; Therneau TM; Roberts LR
Liver Transpl; 2015 May; 21(5):599-606. PubMed ID: 25789635
[TBL] [Abstract][Full Text] [Related]
3. AFP-L3 and DCP are superior to AFP in predicting waitlist dropout in HCC patients: Results of a prospective study.
Mehta N; Kotwani P; Norman J; Shui A; Li PJ; Saxena V; Chan W; Yao FY
Liver Transpl; 2023 Oct; 29(10):1041-1049. PubMed ID: 37159217
[TBL] [Abstract][Full Text] [Related]
4. Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models.
Wongjarupong N; Negron-Ocasio GM; Chaiteerakij R; Addissie BD; Mohamed EA; Mara KC; Harmsen WS; Theobald JP; Peters BE; Balsanek JG; Ward MM; Giama NH; Venkatesh SK; Harnois DM; Charlton MR; Yamada H; Algeciras-Schimnich A; Snyder MR; Therneau TM; Roberts LR
World J Gastroenterol; 2018 Mar; 24(12):1321-1331. PubMed ID: 29599607
[TBL] [Abstract][Full Text] [Related]
5. Clinical Significance of Preoperative Hepatocellular Carcinoma With High
Yamao T; Yamashita YI; Imai K; Umezaki N; Tsukamoto M; Kitano Y; Arima K; Miyata T; Nakagawa S; Okabe H; Hayashi H; Chikamoto A; Ishiko T; Baba H
Anticancer Res; 2019 Feb; 39(2):883-889. PubMed ID: 30711971
[TBL] [Abstract][Full Text] [Related]
6. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
[TBL] [Abstract][Full Text] [Related]
7. Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma.
Sterling RK; Jeffers L; Gordon F; Venook AP; Reddy KR; Satomura S; Kanke F; Schwartz ME; Sherman M
Clin Gastroenterol Hepatol; 2009 Jan; 7(1):104-13. PubMed ID: 18849011
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of alpha-fetoprotein,
Song T; Wang L; Su B; Zeng W; Jiang T; Zhang T; Sun G; Wu H
J Int Med Res; 2020 Mar; 48(3):300060519889270. PubMed ID: 31852373
[TBL] [Abstract][Full Text] [Related]
9. Novel Lens culinaris agglutinin-reactive fraction of α-fetoprotein: a biomarker of hepatocellular carcinoma recurrence in patients with low α-fetoprotein concentrations.
Morimoto M; Numata K; Nozaki A; Kondo M; Moriya S; Taguri M; Morita S; Konno M; Sugo A; Miyajima E; Maeda S; Tanaka K
Int J Clin Oncol; 2012 Aug; 17(4):373-9. PubMed ID: 21847534
[TBL] [Abstract][Full Text] [Related]
10. DCP and AFP-L3 Are Complementary to AFP in Predicting High-Risk Explant Features: Results of a Prospective Study.
Kotwani P; Chan W; Yao F; Mehta N
Clin Gastroenterol Hepatol; 2022 Mar; 20(3):701-703.e2. PubMed ID: 33524592
[TBL] [Abstract][Full Text] [Related]
11. Baseline Alpha-Fetoprotein, Alpha-Fetoprotein-L3, and Des-Gamma-Carboxy Prothrombin Biomarker Status in Bridge to Liver Transplant Outcomes for Hepatocellular Carcinoma.
Núñez KG; Sandow T; Fort D; Patel J; Hibino M; Carmody I; Cohen AJ; Thevenot P
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638251
[TBL] [Abstract][Full Text] [Related]
12. AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC.
Yamamoto K; Imamura H; Matsuyama Y; Kume Y; Ikeda H; Norman GL; Shums Z; Aoki T; Hasegawa K; Beck Y; Sugawara Y; Kokudo N
J Gastroenterol; 2010 Dec; 45(12):1272-82. PubMed ID: 20625772
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic performance of alpha-fetoprotein, lens culinaris agglutinin-reactive alpha-fetoprotein, des-gamma carboxyprothrombin, and glypican-3 for the detection of hepatocellular carcinoma: a systematic review and meta-analysis protocol.
Huang TS; Shyu YC; Turner R; Chen HY; Chen PJ
Syst Rev; 2013 Jun; 2():37. PubMed ID: 23738605
[TBL] [Abstract][Full Text] [Related]
14. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma.
Marrero JA; Feng Z; Wang Y; Nguyen MH; Befeler AS; Roberts LR; Reddy KR; Harnois D; Llovet JM; Normolle D; Dalhgren J; Chia D; Lok AS; Wagner PD; Srivastava S; Schwartz M
Gastroenterology; 2009 Jul; 137(1):110-8. PubMed ID: 19362088
[TBL] [Abstract][Full Text] [Related]
15. The Performance of AFP, AFP-3, DCP as Biomarkers for Detection of Hepatocellular Carcinoma (HCC): A Phase 3 Biomarker Study in the United States.
Tayob N; Kanwal F; Alsarraj A; Hernaez R; El-Serag HB
Clin Gastroenterol Hepatol; 2023 Feb; 21(2):415-423.e4. PubMed ID: 35124267
[TBL] [Abstract][Full Text] [Related]
16. Combined measurement of preoperative α-fetoprotein and des-γ-carboxy prothrombin predicts recurrence after curative resection in patients with hepatitis-B-related hepatocellular carcinoma.
Chon YE; Choi GH; Lee MH; Kim SU; Kim DY; Ahn SH; Kim KS; Choi JS; Han KH; Chon CY; Park JY
Int J Cancer; 2012 Nov; 131(10):2332-41. PubMed ID: 22362471
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein-L3 and seronegative for des-gamma-carboxy prothrombin in comparison with those seropositive for des-gamma-carboxy prothrombin alone.
Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Yamamoto M; Takasaki K; Nakano M
J Gastroenterol Hepatol; 2002 Jul; 17(7):772-8. PubMed ID: 12121507
[TBL] [Abstract][Full Text] [Related]
18. Des-γ carboxyprothrombin may not be a good biomarker for hepatocellular carcinoma in those chronically infected with hepatitis B virus with basal core promoter double mutations (T^{1762}, A^{1764}), a prospective study.
Li GJ; Chen QY; Harrison TJ; Wang XY; Hu LP; Yang QL; Li KW; Fang ZL
Cancer Biomark; 2017; 18(3):241-248. PubMed ID: 28085009
[TBL] [Abstract][Full Text] [Related]
19. Analysis of serum α-fetoprotein-L3% and des-γ carboxyprothrombin markers in cases with misleading hepatocellular carcinoma total α-fetoprotein levels.
Hadziyannis E; Sialevris K; Georgiou A; Koskinas J
Oncol Rep; 2013 Feb; 29(2):835-9. PubMed ID: 23174906
[TBL] [Abstract][Full Text] [Related]
20. Clinical utility of simultaneous measurement of serum high-sensitivity des-gamma-carboxy prothrombin and Lens culinaris agglutinin A-reactive alpha-fetoprotein in patients with small hepatocellular carcinoma.
Sassa T; Kumada T; Nakano S; Uematsu T
Eur J Gastroenterol Hepatol; 1999 Dec; 11(12):1387-92. PubMed ID: 10654799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
